Heart Failure and Loss of Metabolic Control

被引:67
作者
Wang, Zhao V. [1 ]
Li, Dan L. [1 ]
Hill, Joseph A. [1 ,2 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Div Cardiol, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
heart failure; metabolism; GLUCAGON-LIKE PEPTIDE-1; FATTY-ACID OXIDATION; ACTIVATED-RECEPTOR-ALPHA; LEFT-VENTRICULAR PERFORMANCE; ACUTE MYOCARDIAL-INFARCTION; INSULIN-POTASSIUM INFUSION; CONTRACTILE DYSFUNCTION; PREFERENTIAL OXIDATION; SUBSTRATE UTILIZATION; ENERGY-METABOLISM;
D O I
10.1097/FJC.0000000000000054
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Heart failure is a leading cause of morbidity and mortality worldwide, currently affecting 5 million Americans. A syndrome defined on clinical terms, heart failure is the end result of events occurring in multiple heart diseases, including hypertension, myocardial infarction, genetic mutations and diabetes, and metabolic dysregulation, is a hallmark feature. Mounting evidence from clinical and preclinical studies suggests strongly that fatty acid uptake and oxidation are adversely affected, especially in end-stage heart failure. Moreover, metabolic flexibility, the heart's ability to move freely among diverse energy substrates, is impaired in heart failure. Indeed, impairment of the heart's ability to adapt to its metabolic milieu and associated metabolic derangement are important contributing factors in the heart failure pathogenesis. Elucidation of molecular mechanisms governing metabolic control in heart failure will provide critical insights into disease initiation and progression, raising the prospect of advances with clinical relevance.
引用
收藏
页码:302 / 313
页数:12
相关论文
共 141 条
[1]
Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy [J].
Abel, E. Dale ;
Doenst, Torsten .
CARDIOVASCULAR RESEARCH, 2011, 90 (02) :234-242
[2]
Insulin signaling in heart muscle: Lessons from genetically engineered mouse models [J].
Abel, ED .
CURRENT HYPERTENSION REPORTS, 2004, 6 (06) :416-423
[3]
Glucose transport in the heart [J].
Abel, ED .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :201-215
[4]
Allard MF, 1997, CIRCULATION, V96, P676
[5]
Glycogen storage diseases presenting as hypertrophic cardiomyopathy [J].
Arad, M ;
Maron, BJ ;
Gorham, JM ;
Johnson, WH ;
Saul, JP ;
Perez-Atayde, AR ;
Spirito, P ;
Wright, GB ;
Kanter, RJ ;
Seidman, CE ;
Seidman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (04) :362-372
[6]
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy [J].
Arad, M ;
Benson, DW ;
Perez-Atayde, AR ;
McKenna, WJ ;
Sparks, EA ;
Kanter, RJ ;
McGarry, K ;
Seidman, JG ;
Seidman, CE .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) :357-362
[7]
Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up [J].
Ärnlöv, J ;
Lind, L ;
Zethelius, B ;
Andrén, B ;
Hales, CN ;
Vessby, B ;
Lithell, H .
AMERICAN HEART JOURNAL, 2001, 142 (04) :720-724
[8]
Metabolic mechanisms in heart failure [J].
Ashrafian, Houman ;
Frenneaux, Michael P. ;
Opie, Lionel H. .
CIRCULATION, 2007, 116 (04) :434-448
[9]
Perhexiline [J].
Ashrafian, Houman ;
Horowitz, John D. ;
Frenneaux, Michael P. .
CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (01) :76-97
[10]
BIOCHEMICAL-MECHANISMS OF OXFENICINE CARDIOTOXICITY [J].
BACHMANN, E ;
WEBER, E .
PHARMACOLOGY, 1988, 36 (04) :238-248